REGENXBIO Launches a Manufacturing Facility for Developing Gene Therapies Based on NAV-Technology
Shots:
- REGENXBIO plans to construct a cGMP manufacturing facility in Rockville- Maryland to produce gene therapy vectors based on NAV technology at scales up to 2-000L using its platform suspension cell culture process
- The addition of new cGMP manufacturing facility complements current external manufacturing capabilities- enabling a supply of NAV vectors from both internal and external sources meeting global regulatory requirements and is expected to be operational in 2021
- REGENXBIO's NAV technology is a gene delivery platform contains an exclusive right to 100+ novel AAV vectors including AAV7- AAV8- AAV9 and AAVrh10 and is used to develop therapies for multiple indications
Ref: REGENXBIO | Image: Solebury Trout Access
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com